Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.

Hagop M KantarjianWendy StockRyan D Cassaday Daniel J DeAngeloElias JabbourSusan M O'BrienMatthias StelljesTao WangM Luisa PaccagnellaKevin NguyenBarbara SleightErik VandendriesAlexander NeuhofA Douglas LairdAnjali S Advani

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Inotuzumab ozogamicin demonstrated a favorable benefit-risk profile versus SC in patients with higher and lower CD22 expression. Patients with high CD22 expression and normal cytogenetics benefited the most from inotuzumab ozogamicin therapy.

Keyphrases

acute lymphoblastic leukemia
poor prognosis
allogeneic hematopoietic stem cell transplantation
nk cells
clinical trial
stem cells
randomized controlled trial
binding protein
study protocol
mesenchymal stem cells
diffuse large b cell lymphoma
phase ii
open label
hodgkin lymphoma